Search results for "Therapeutic strategy"

showing 10 items of 17 documents

Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of …

2016

The recent advances in identification of the molecular mechanisms related to tumorigenesis and angiogenesis, along with the understanding of molecular alterations involved in renal cell carcinoma (RCC) pathogenesis, has allowed the development of several new drugs which have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). This process has resulted in clinically significant improvements in median overall survival and an increasing number of patients undergoes two or even three lines of therapy. Therefore, it is necessary a long-term perspective of the treatment: planning a sequential and personalized therapeutic strategy to improve clinical outcome, the potential to a…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practicemedicine.drug_classSettore MED/06 - Oncologia MedicaVEGF receptorsAntineoplastic AgentsReviewurologic and male genital diseasesrenal cell cancerTyrosine-kinase inhibitor03 medical and health sciencesangiogenesis0302 clinical medicinetyrosine kinase inhibitorQuality of lifeRenal cell carcinomaInternal medicineAngiogenesis; MTOR; Renal cell cancer; Tyrosine kinase inhibitor; VEGFr; OncologymedicineOverall survivalAnimalsHumansMolecular Targeted TherapyPrecision MedicineCarcinoma Renal CellTherapeutic strategybiologybusiness.industryPrecision medicinemedicine.diseaseKidney NeoplasmsSurgeryAngiogenesiSettore MED/18 - Chirurgia GeneraleVEGFr030104 developmental biologyOncology030220 oncology & carcinogenesisbiology.proteinmTORbusiness
researchProduct

Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential

2018

Abstract: Introduction: Pancreatic neuroendocrine tumors (pNETs) represent a small part of pancreatic neoplasms, and the knowledge about their indolent clinical course remains a subject of investigation. They occur sporadically or as part of familial cancer syndromes and are classified by WHO in 3 categories. There is ongoing research to understand their molecular profiling and leading mutations.Areas covered: The aim of this review is to clarify the overall aspects of tumorigenesis, to expose the latest developments in understanding the course of the disease and the possible therapeutic implications of these. The review also discusses functional and non-functional pNETs and associated inhe…

0301 basic medicineSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical Decision-MakingAntineoplastic AgentsDiseaseNeuroendocrine tumorsBioinformaticsTargeted therapy03 medical and health sciences0302 clinical medicinePredictive Value of TestsFunctional tumorBiomarkers TumormedicineHumansProfiling (information science)Molecular Targeted Therapyneurondocrine tumorPrecision MedicineTherapeutic strategymolecular pathwayHepatologybusiness.industryGene Expression ProfilingGastroenterologyClinical coursehereditary syndrometargeted therapymedicine.diseaseGene Expression Regulation NeoplasticPancreatic NeoplasmsNeuroendocrine Tumors030104 developmental biology030220 oncology & carcinogenesispancreatic tumorFamilial CancerHuman medicinebusinessSignal TransductionExpert review of gastroenterology & hepatology
researchProduct

Resveratrol and stroke: from chemistry to medicine.

2014

Stroke is one of the most common cardiovascular diseases and is known as a leading cause of death in the world. Despite to its high prevalence, there are limited effective therapeutic strategies for stroke till now. However, oxidative stress plays an important role in the pathogenesis of stroke and therefore, antioxidant therapy could be used as a new therapeutic strategy. Among the antioxidants, some natural compounds are very interesting due to their low adverse effects. Resveratrol (3, 5, 4'-trihydroxystilbene) is a natural polyphenolic antioxidant found in grape skin, grape products, and peanuts as well as in red wine. In recent years, much attention has been paid to resveratrol due to …

Antioxidantmedicine.medical_treatmentBiological AvailabilityPharmacologyResveratrolmedicine.disease_causeAntioxidantsNitric oxideCellular and Molecular Neurosciencechemistry.chemical_compoundDevelopmental NeuroscienceStilbenesmedicineAnimalsHumansAdverse effectStrokeTherapeutic strategyHigh prevalencebusiness.industryfood and beveragesmedicine.diseaseStrokeNeurologychemistryResveratrolbusinessOxidative stressCurrent neurovascular research
researchProduct

Cutaneous Lupus Erythematosus

2008

Lupus erythematosus (LE) is an inflammatory autoimmune disease, characterized by a heterogeneous clinical presentation. The skin lesions are one of the most frequent symptoms of the disease and present with a broad spectrum of LE-nonspecific and LE-specific cutaneous manifestations. Therefore, the development of a classification for skin lesions in the disease has proven difficult. For example, the LE-nonspecific cutaneous manifestations include livedo racemosa, thrombophlebitis, and leukocytoclastic vasculitis and can be associated with high disease activity and systemic organ involvement. The LE-specific cutaneous manifestations encompass the subtypes of cutaneous lupus erythematosus (CLE…

Autoimmune diseasemedicine.medical_specialtyLupus erythematosusmedicine.diagnostic_testbusiness.industryfungiDiseaseLivedo racemosamedicine.diseaseThrombophlebitisDermatologySkin biopsyPhototestingmedicineCutaneous Lupus ErythematosusAntimalarial Agentmedicine.symptombusinessPanniculitisSkin lesionTherapeutic strategyAnti-SSA/Ro autoantibodies
researchProduct

Factors influencing inclusion in digestive cancer clinical trials: A population-based study

2015

Inclusion in a randomized therapeutic trial represents an optimal therapeutic strategy.To determine the influence of demographic characteristics and deprivation on the enrolment of patients in digestive cancer clinical trials.Between 2004 and 2010, 4632 patients were recorded by the Burgundy Digestive Cancer Registry. According to a balancing score, the 136 patients included in a clinical trial were matched with 272 patients who met the eligibility criteria for trials. Deprivation was measured by the ecological European deprivation index. A conditional multivariate logistic regression was performed.Patients aged over 75 years were significantly less likely to be included in clinical trials …

Clinical Trials as TopicPediatricsmedicine.medical_specialtyMultivariate analysisHepatologybusiness.industryPatient SelectionAge FactorsGastroenterologyOdds ratioLogistic regressionClinical trialPopulation based studyLogistic ModelsSocioeconomic FactorsMultivariate AnalysismedicineHumansRegistriesbusinessInclusion (education)Digestive cancerGastrointestinal NeoplasmsTherapeutic strategyDigestive and Liver Disease
researchProduct

Antitumoral activity of curcumin: an adjuvant therapeutic strategy

2021

Curcumin, an active substance contained in an Indian spice called turmeric or curcuma, is well known for its anti-inflammatory and antioxidant properties. In recent times, it was taken into account and studied as an antitumoral molecule, by relying on its interference on several biological mechanisms, such as the inhibition of inflammatory mediators, the enhancement of detoxifying enzymes’ action and processes of cell growth and proliferation. Studies show how the high dosage of curcumin in vitro inhibits colorectal tumor cells, pancreatic tumor cells, lung cancer cells and glioblastoma’s cells, interfering in signaling pathways as Wnt/β-catenin, NF-kB and PI3K/Akt and leading to cell cycle…

Curcumincolorectal tumors antioxidants curcumin antinflammatory effects pancratic cancerbusiness.industryBiochemistry (medical)Plant SciencePharmacologyGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundnutritionSettore MED/03 - Genetica Medicachemistrycolon cancerlcsh:Biology (General)CurcuminMedicinechemopreventionantitumor activity5-fluorouracilbusinesslcsh:QH301-705.5Therapeutic strategyJournal of Biological Research
researchProduct

Indications for Locoregional Tumor Therapies: CRC Liver Metastases

2018

The liver represents the most affected site in patients affected by colorectal carcinoma (mCRC) [1]. More than half cases develop colorectal liver metastases (CLMs) during the evolution of the disease, and about one-quarter occur at the disease onset [1, 2]. To date, the standard treatment of CLM is represented by liver surgery, which has allowed to achieve interesting long-term survival rates (40-60%) [3] in reported series, while it is less than 25% for patients who do not undergo surgery [4]. Unfortunately, most patients (80%), however, are not immediately eligible for surgery [5, 6]. For these patients, surgical treatment may be administered in combination with chemotherapy regimens (+/…

Liver surgerymedicine.medical_specialtyChemotherapySettore MED/06 - Oncologia Medicabusiness.industryColorectal cancermedicine.medical_treatmentStandard treatmentCRC liver metastasesDiseasemedicine.diseaseSurgeryQuality of lifemedicineIn patientbusinessTherapeutic strategy
researchProduct

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta…

2019

Background: Tissue evaluation for RAS (KRAS or NRAS) gene status in metastatic colorectal cancer (mCRC) patients represent the standard of care to establish the optimal therapeutic strategy. Unfortunately, tissue biopsy is hampered by several critical limitations due to its invasiveness, difficulty to access to disease site, patient’s compliance and, more recently, neoplastic tissue spatial and temporal heterogeneity. Methods: The authors performed a systematic literature review to identify available trials with paired matched tissue and ctDNA RAS gene status evaluation. The authors searched EMBASE, MEDLINE, Cochrane, www.ClinicalTrials.gov , and abstracts from international meetings. In to…

Neuroblastoma RAS viral oncogene homologOncologymedicine.medical_specialtyStandard of careColorectal cancerSettore MED/06 - Oncologia Medicamedicine.disease_causelcsh:RC254-282meta-analysi03 medical and health sciences0302 clinical medicineInternal medicinemedicineLiquid biopsy030304 developmental biologyTherapeutic strategycirculating tumor DNAcirculating tumor DNA; diagnostic accuracy; liquid biopsy; meta-analysis; metastatic colorectal cancer; RAS0303 health sciencesliquid biopsybusiness.industrymetastatic colorectal cancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthmeta-analysisOncologyCirculating tumor DNA030220 oncology & carcinogenesisMeta-analysisdiagnostic accuracyKRASbusinessRAS
researchProduct

Transarterial chemoembolization and sorafenib in hepatocellular carcinoma

2014

Transarterial chemoembolization (TACE) is considered as the standard therapy for patients with intermediate-stage hepatocellular carcinoma. However, given the high heterogeneity of this population, no common strategy or protocol standardization has been defined yet. In the last few years TACE treatment has been combined with sorafenib systemic therapy, reporting overall positive results both in terms of safety and efficacy. This systematic review presents and critically discusses the evidence available on the use of TACE in combination (concomitant or sequential) with sorafenib, focusing also on clinical trials currently ongoing to better define an optimal therapeutic strategy for this grou…

NiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularCombination therapyPopulationAntineoplastic AgentsSystemic therapyInternal medicinemedicineHumansPharmacology (medical)Chemoembolization TherapeuticeducationTherapeutic strategyClinical Trials as Topiceducation.field_of_studybusiness.industryPhenylurea CompoundsLiver NeoplasmsSorafenibmedicine.diseaseClinical trialOncologyHepatocellular carcinomaConcomitantRadiologybusinessmedicine.drugExpert Review of Anticancer Therapy
researchProduct

Liquid Biopsy in Colorectal Cancer

2017

Colorectal cancer (CRC) is the third most common cancer worldwide. Oncological CRC treatment is changing gradually replacing ancient drugs with the newest targeted agents (target therapy) and immunotherapy. The correct use of these molecular agents is based on a series of genetic evaluations able to predict treatment response. The tissue evaluation of these predictors is generally fully of serious limitations among which the invasiveness of the tissue biopsy procedure and its non-informative quality compared to the entire neoplastic mass. For these reasons, liquid biopsy could represent an ideal tool to obtain easily and quickly the necessary information to decide the best therapeutic strat…

OncologyTreatment responsemedicine.medical_specialtyColorectal cancerbusiness.industrymedicine.medical_treatmentCancerImmunotherapymedicine.diseaseInternal medicinemedicineTarget therapyLiquid biopsybusinessTissue biopsyTherapeutic strategy
researchProduct